logo
The CEO of Life Time says he takes 45-50 supplements a day for healthy aging. Here's how he decides what to include.

The CEO of Life Time says he takes 45-50 supplements a day for healthy aging. Here's how he decides what to include.

Yahoo05-02-2025
The CEO of Life Time Fitness says he takes about 45-50 supplements every morning.
But he doesn't want you copying his strategy.
He gets bloodwork done regularly, a technique longevity doctors endorse.
Bahram Akradi says that he's so fit, he can challenge people half his age at the gym.
"At 63, I'm competing with 33-year-olds," the CEO of Life Time Fitness told Business Insider.
He says folks who observe his daily routines and rituals often want to know his secrets for staying strong and healthy.
"They say, 'tell me what you're taking,' and I'm like, 'well, what I'm taking is customized to me. You don't need to be taking what I'm taking.'"
He subscribes to the same supplement-taking strategy that's become increasingly popular in longevity circles and at specialty clinics around the world: "Precision medicine." Test, then treat, according to your own results.
For Akradi, the technique is nothing new. He says he's been taking "about 45 to 50" pills every morning for many years. Not every capsule is unique; he estimates there are about 35 to 40 different compounds in the mix.
"I have been doing what I'm doing for the last 15 years," he said. Every four months, he goes in for testing to reassess his regimen. "I do my blood work, and I adjust my supplements."
Most doctors would tell you this is probably overkill. Comprehensive bloodwork like this can cost hundreds, if not thousands, of dollars.
Besides, getting bloodwork done once a year at an annual exam (ideally, one that's covered by insurance) is likely good enough to gauge what major supplement changes may be in order. But Akradi thinks of this as his own form of high-end seasonal housekeeping.
"My routine is: do my blood work every 120 days and then, 'oh, I don't have enough zinc in my deal,' add a little zinc. Or I have too much iron, take a little iron out," he said. "My strong recommendation to people, if they can afford it, is: don't take supplements generically."
In 2024, Akradi took a stab at his dream: adding a longevity clinic to a Life Time gym near the company's headquarters in Minneapolis.
The clinic, called Miora, sits in the posh, underground branch of Life Time below the arena where the Minnesota Timberwolves play. Doctors on staff can prescribe supplements and medications, including GLP-1 drugs for weight loss. "You come in, we take your blood, we go through your assessment," Akradi said.
Miora doesn't take insurance, sidestepping the US healthcare system and getting customers to pay out of pocket. Within six months, Akradi said, the clinic was profitable.
This is Life Time's second foray into clinical care. Akradi tried once, over a decade ago, to pivot into doctor's office care for gym-goers when he established the first "LT Proactive Care" clinic in 2013. The model relied on insurance and didn't work so well. Those clinics all eventually closed.
With one solid proof of concept, Akradi is planning to open at least two more Miora clinics before the end of Q1 2025, one in Florida and the other in Illinois. He views it as a natural evolution for the fitness company he founded in 1992, trying to show that Life Time is a complement — not an alternative — to alluring quick fixes, like diets and weight-loss pills.
"The goal was to build a fully integrated, healthy living and healthy aging company," he said.
Miora isn't the only place doing tailored supplement prescriptions.
There are longevity clinics sprouting up around the world taking a similar approach to supplementation — deciding a regimen based on bloodwork.
Andrea Maier, one of the leading academic supplement researchers in aging and longevity, says less is usually more when it comes to supplements for longevity.
"In our clinic, we are de-prescribing," Maier recently told Business Insider. "We first have to diagnose what's wrong, what somebody needs, and that might differ."
Read the original article on Business Insider
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

C-suite shuffles ripple through pharma
C-suite shuffles ripple through pharma

Yahoo

time2 hours ago

  • Yahoo

C-suite shuffles ripple through pharma

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. If Novo Nordisk aimed to boost confidence in the company's future course by naming a new CEO, those hopes were dashed this week. The weight loss and diabetes juggernaut announced that Maziar Mike Doustdar — a long-time company executive — is taking the reins on Tuesday, calling him the 'best person' to lead Novo into its 'next growth phase.' Novo shares plunged over 20% after the news came out — its largest single-day drop ever recorded. Of course, there's much more to Novo's story than the CEO news, which comes as the industry grapples with a range of market challenges, including widespread regulatory changes, potential tariffs, patent cliffs and more. In fact, Novo is one of several large pharmas to shake up their top brass this month. Here's more on Novo's major leadership transition and other companies attempting to right the ship with a fresh face behind the wheel. Novo's descent back to earth After its weight-loss-fueled ascent to the sales stratosphere, Novo is working to try to keep its growth sky high. In May, the Danish pharma said CEO Lars Fruergaard Jørgensen would step down, following a turn in the obesity market. While Novo was the star of the emerging weight loss and diabetes market through its GLP-1s Ozempic and Wegovy, Eli Lilly took over the majority of the market officially earlier this year thanks to growing popularity for Zepbound and Wegovy. The switchup brought Novo back to the drawing board for a rebound. This week, while naming its new CEO, the company also cut its guidance for 2025 from a sales increase of 13% to 21% to between 8% and 14% after slower-than-expected uptake of its GLP-1 products. Doustdar is now tasked with the challenge of navigating Novo's new era as the second-place obesity leader, grappling with slower growth, potential incoming competitors and compounded versions of its drugs still available on the cheap for some patients. Doustdar has been with Novo for more than 30 years, most recently serving as executive vice president of international operations after getting his start as an office clerk in Vienna during the 1990s. He oversaw the launch of Novo's GLP-1s in several countries, and could tighten up the ship with workforce cuts once at the helm in August, The Wall Street Journal reported. 'I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done,' he said in a statement. Amid the changes at the top, Novo also restructured its R&D, combining two divisions into one, which will be led by the company's newly appointed chief scientist, Dr. Martin Holst Lange. Kenvue's shaky future Johnson & Johnson's decision to spin off its consumer health business in 2023 followed a wave of similar moves by major pharma companies such as Sanofi and GSK. The goal was to streamline, simplify and refocus on the business of innovating drugs. But since going it alone, J&J's spinoff Kenvue has struggled to find its footing as a mammoth, multi-faceted company with a broad OTC drug portfolio including stalwarts such as Tylenol and Benadryl, along with household favorite brands like Aveeno and Listerine. Several headwinds — including falling sales at retail pharmacies — have triggered pressure from activist investors to make a change. Starboard Value already has a seat on the company's board, and earlier this year Third Point and Toms Capital bought up more of its stock. With Kenvue in the midst of a strategic review, CEO Thibaut Mongon was ousted suddenly this month and replaced by interim head Kirk Perry, the company's board director. While the company touted Perry's 30 years of leadership in consumer packaged goods, it said an executive search firm has been hired to lead the quest for its next permanent CEO. In its preliminary earnings report for the most recent quarter, Kenvue said it expects a 4% sales drop. News of the shift has fueled investor speculation that Kenvue is preparing to sell some of its brands or setting the stage for an outright acquisition of the company, which is currently valued at $40 billion. Jazz sings new tune with CEO switch Jazz Pharmaceuticals made history by scoring the first FDA approval for a CBD-based drug in 2018. Now, Epidiolex, which is indicated for two rare forms of epilepsy, is on its way to crossing the blockbuster threshold this year, providing an ample revenue cushion for the company's ongoing pursuit of M&A. But Jazz's next big act could be in oncology. The Ireland-based biopharma picked up Chimerix this year for $935 million to nab a brain tumor candidate, potentially building on a portfolio that also includes a HER2-targeting bispecific antibody that's already won an accelerated approval in one cancer indication and is being studied in several more. Citeline has pegged the treatment, Ziihera, as a potential blockbuster. With its future coming into sharper focus, Jazz announced new leadership plans this month. Renée Galá will step into the CEO role in August as former CEO Bruce Cozadd retires. Galá became the company's president and chief operating officer in 2023 and brings over 30 years of industry experience to the post The promotion will also make Galá, whom the company said has played a 'critical role in driving Jazz's ongoing transformation.' Recommended Reading Turning the page: Novo's CEO transition reflects Big Pharma's era of change

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

Yahoo

time17 hours ago

  • Yahoo

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

Health-related stocks are not having a good day. First, America's largest health insurance provider, UnitedHealth Group (NYSE: UNH), saw its stock drop more than 4% this morning after the company announced disappointing second-quarter results and a full-year 2025 forecast that concerned investors. And now, the Danish pharmaceutical giant Novo Nordisk A/S, whose shares (NYSE: NVO) trade on the New York Stock Exchange, is seeing its stock price plunge, too. The real reason a staggering 40% of U.S. homeowners are mortgage-free Tsunami warning tracker: Map and online tool let you follow alerts in real time after massive earthquake Figma's IPO date is close. The stock could trade even higher after the design startup's latest move Currently, NVO shares are down more than 20% at the time of this writing. But unlike UnitedHealth Group, Novo Nordisk has not reported its most recent quarterly results. So what's sending its shares lower? Here's what you need to know. Novo Nordisk cuts full-year 2025 guidance The main driver of Novo Nordisk's significant share price fall today is the company's announcement that it is revising its previously published sales growth and operating profit growth for its full fiscal year 2025. On May 7, Novo Nordisk stated that it expected full-year fiscal 2025 sales growth to be between 13% and 21%. At the same time, it said it expected its operating profit growth to be between 16% and 24%. Now, however, the company had drastically cut both forecasts. Novo Nordisk now says it expects full-year fiscal 2025 sales growth to be between 8% and 14% and operating profit growth to be between 10% and 16%. In a statement, the company said its 'lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025.' This lowered growth is due to lower growth expectations for its GLP-1 weight loss and diabetes drugs, Wegovy and Ozempic, in the U.S. market. 'For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition,' the company said. It added that as far as Ozempic was concerned, 'the updated outlook is negatively impacted by competition in the U.S.' Novo Nordisk's main competitor in the GLP-1 arena is the American pharmaceutical giant Eli Lilly, who makes the drugs Mounjaro and Zepbound. Novo Nordisk names new CEO Besides revising its 2025 growth forecasts downward, Novo Nordisk also made another announcement today: It named a new CEO. However, this announcement probably had little to do with the stock's fall this morning. Back in May, Novo Nordisk announced that its longtime CEO Lars Fruergaard Jørgensen would be stepping aside. At the time, the company cited its declining share price as one of the reasons for the CEO shakeup. It also said Jørgensen would stay on as CEO until a successor was found. Now, one has been. Today, Novo Nordisk announced that Maziar Mike Doustdar will be assuming the position of president and chief executive officer, effective August 7, 2025. Doustdar is currently the company's executive vice president of international operations. Announcing Doustdar's ascent to the CEO role, Novo Nordisk chair Helge Lund said: 'This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Doustdar will officially take over as CEO one day after the company reports its second quarter 2025 results on August 6. Novo Nordisk shares have fallen dramatically since last summer While the GLP-1 drugs Wegovy and Ozempic have been a massive source of growth and profits at Novo Nordisk in the first half of this decade, recently, the company has faced increased competition in the GLP-1 marketplace, which has partly contributed to investor concerns. Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down more than 57%. And since the beginning of 2025, the company's share price has declined more than 35%. As of the time of this writing, NVO shares are down just over 20% this morning to $55.17 per share. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio

Wegovy maker Novo's profit warning triggers $70 billion share rout
Wegovy maker Novo's profit warning triggers $70 billion share rout

Yahoo

time20 hours ago

  • Yahoo

Wegovy maker Novo's profit warning triggers $70 billion share rout

By Jacob Gronholt-Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started. Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down over 20% by mid-afternoon. The shares are now down 44% this year. "The magnitude of the guidance cut is a shocker," Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than "compounded" copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. U.S. law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations. The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the U.S., both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen. At its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market. "The stock has gone from being a market darling to one of its biggest letdowns," said Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, which has a small Novo stake. "The biggest concern is the illegal channel siphoning away market share - something that's hard to quantify. Rebuilding trust will take time." NEW CEO AN INSIDER Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7. He currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. "We need to increase the sense of urgency and execute differently," Doustdar told investors and analysts on a call. "The fact that my announcement comes right after the guidance update, just makes the mandate ahead even more clear." Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to U.S. rival Eli Lilly. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. In May, Novo said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22. "Unfortunately, our latest market research indicates that has not happened," Chief Financial Officer Karsten Munk Knudsen said on a call with analysts on Tuesday. One million or more U.S. patients are still using compounded GLP-1s, he said. Novo has stepped up its dialogue with the U.S. FDA to limit unlawful compounding of its drugs, the head of U.S. operations David Moore added on the call. "Compounding continues to be an issue that we have to address," Moore said. ($1 = 0.8672 euros) Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store